InnovoTEX Inc.
About InnovoTEX Inc.
InnovoTEX Inc. is a pharmaceutical company advancing Macrocycle Drug Conjugates (MDCs), a novel class of tumor-selective oncology therapeutics engineered to improve intratumoral penetration, selective retention, and therapeutic durability. The company's lead candidate, NOVO-111, combines a tumor-selective texaphyrin macrocycle with an oxaliplatin payload to enhance tumor drug exposure while significantly minimizing systemic toxicity across solid tumors. InnovoTEX is redefining cancer treatment with a clinically de-risked drug delivery pipeline engineered to select aggressive, treatment-resistant tumors and improve durability. The company is pioneering macrocycle drug conjugates to transform the treatment paradigm.
- 🔗 Innovotex Raises $750K Seed Funding
- 🔗 INNOVOTEX Appoints Dr. Krystle Karoscik as CEO to Advance Macrocycle Drug Conjugate Platform into the Clinic - Knox News | The Knoxville News-Sentinel
- 🔗 INNOVOTEX 2026 Company Profile
- 🔗 INNOVOTEX Announces Company Overview to Highlight Advancement of NOVO-111 and Macrocycle Drug Conjugate Platform - Cincinnati.com | The Enquirer
- 🔗 INNOVOTEX Inc.
Key highlights
- InnovoTEX has raised $749,951 in a Private Placement round
- The company is developing Macrocycle Drug Conjugates (MDCs) for cancer treatment
- The lead candidate, NOVO-111, is on track for clinical trials
Ask StreetZero about InnovoTEX Inc.
Put our AI to work on this deal.
Similar companies
Other Pharmaceuticals deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account